Efficacy and safety of edaravone dexcamphenol in the treatment of acute cerebral infarction
- VernacularTitle:依达拉奉右莰醇注射用浓溶液治疗急性脑梗死的疗效与安全性观察
- Author:
Qianqian WANG
1
;
Bin LIU
1
;
Juan GUO
1
Author Information
- Publication Type:Journal Article
- Keywords: Acute cerebral infarction ； Edaravone Dexcamphenol ； Safety ； Efficacy
- From: Journal of Apoplexy and Nervous Diseases 2022;39(4):333-335
- CountryChina
- Language:Chinese
- Abstract: Objective To investigate the efficacy and safety of edaravone dexcamphenol in the treatment of acute cerebral infarction.Methods Patients with acute cerebral infarction were randomly divided into observation group (edaravone dexborneol+conventional treatment) and control group (conventional treatment) for 14 days.Neurological function was assessed by the National Institutes of Health Stroke Scale (NIHSS) at admission and the modified Rankin Scale (mRS) at 14 days after treatment,respectively.C-reactive protein (CRP) level was detected simultaneously.Furthermore,the occurrence of adverse drug reactions during treatment was observed.Results NIHSS score,mRS score and CRP levels in experimental group were significantly lower than those in control group (all P<0.05).No adverse drug reactions in the two groups were observed during treatment.Conclusion Edaravone dexborneol has a significant clinical effect in the treatment of acute cerebral infarction,and the safety of this treatment is relatively high.
- Full text:2024072521082693966Efficacy and safety of edaravone dexcamphenol in the treatment of acute cerebral infarction.pdf
